85 research outputs found
Databases breast cancer patients miR-1260a
No full text<p>This work is the study of miR-1260a levels in 50 patients with breast cancer. In this study miR-1260a levels correlate with pathological characteristics of tumors.</p>
<p> </p>Database of miR-1260a in breast cancer patients © 2023 by Matilde E. LLeonart is licensed under CC BY-NC-SA 4.
Ribosomal proteins as novel players in tumorigenesis
No full textRibosome biogenesis is the most demanding energetic and metabolic expenditure of the cell. The nucleolus, a nuclear compartment, coordinates rRNA transcription, maturation, and assembly into ribosome subunits. The transcription process is highly coordinated with ribosome biogenesis. In this context, ribosomal proteins (RPs) play a crucial role. In the last decade, an increasing number of studies have associated RPs with extraribosomal functions related to proliferation. Importantly, the expression of RPs appears to be deregulated in several human disorders due, at least in part, to genetic mutations. Although the deregulation of RPs in human malignancies is commonly observed, a more complex mechanism is believed to be involved, favoring the tumorigenic process, its progression and metastasis. This review explores the roles of the most frequently mutated oncogenes and tumor suppressor genes in human cancer that modulate ribosome biogenesis, including their interaction with RPs. In this regard, we propose a new focus for novel therapies. © 2013 Springer Science+Business Media New York.The current study, including the contract of M. E. LLeonart, was supported by grants from the Ministerio de Sanidad (FIS PI12/01104)Peer Reviewe
Epigenetic mechanisms in senescence, immortalisation and cancer
No full text13 páginas, 5 figuras, 1 tabla.Cancer is controlled not only by genetic events but also by epigenetic events. The active acquisition of epigenetic changes is a poorly understood but very important process in mammalian development, differentiation, and disease. It is well established that epigenetic events are controlled by a specific subgroup of proteins, such as DNA methyltransferases, histone acetylases histone lysine methyltransferases or histone deacetylases, that influence methylation or acetylation patterns to modulate gene expression. We and others have identified S-adenosylhomocysteine hydrolase in a high-throughput genetic screen focused on discovering novel genes whose inhibition induces immortalisation of primary cells. Herein, we address the importance of genes involved in epigenetic mechanisms during senescence and how their effects might determine senescence bypass and immortalisation. The ways in which genes that regulate epigenetic mechanisms might modulate senescence/immortalisation and how these pathways could influence cancer development are explored. Overall, epigenetic modifications seem to play a major role in cancer, influencing tumour outcome by interfering with key senescence pathways.This study was supported by grants from the Ministerio de Ciencia e Innovacion (SAF2009-08605) and Consejeria de Salud of the Junta de Andalucia (PI-0142) to A.C. and a Marato TV3 project 052130 and AGAUR (Agència de Gestió dÁjuts Universitaris i de Recerca) SGR604 to M.E.LL. M.E.LL is a FIS investigator (CP03/00101).Peer reviewe
Inestabilidad en microsatélites y mutaciones del gen p53 en el cáncer de colon derecho e izquierdo: correlación clínico-patológica
No full textTesis doctoral inédita, leía en la Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Biología Molecular . Fecha de lectura: 3-6-199
Editorial: Sphingolipid metabolism and cancer
No full textCancer; Metabolism; SphingolipidCáncer; Metabolismo; EsfingolípidoCàncer; Metabolisme; Esfingolípi
Editorial : Reciprocal crosstalk between the tumor microenvironment and cancer stem cells
No full textPeer reviewe
Inestabilidad en microsatelites y mutaciones del gen p53 en el cancer de colon derecho e izquierdo Correlacion clinico-patologica
No full textCentro de Informacion y Documentacion Cientifica (CINDOC). C/Joaquin Costa, 22. 28002 Madrid. SPAIN / CINDOC - Centro de Informaciòn y Documentaciòn CientìficaSIGLEESSpai
Targeting Sphingolipids for Cancer Therapy
No full textSphingolipids are an extensive class of lipids with different functions in the cell, ranging from proliferation to cell death. Sphingolipids are modified in multiple cancers and are responsible for tumor proliferation, progression, and metastasis. Several inhibitors or activators of sphingolipid signaling, such as fenretinide, safingol, ABC294640, ceramide nanoliposomes (CNLs), SKI-II, α-galactosylceramide, fingolimod, and sonepcizumab, have been described. The objective of this review was to analyze the results from preclinical and clinical trials of these drugs for the treatment of cancer. Sphingolipid-targeting drugs have been tested alone or in combination with chemotherapy, exhibiting antitumor activity alone and in synergism with chemotherapy in vitro and in vivo. As a consequence of treatments, the most frequent mechanism of cell death is apoptosis, followed by autophagy. Aslthough all these drugs have produced good results in preclinical studies of multiple cancers, the outcomes of clinical trials have not been similar. The most effective drugs are fenretinide and α-galactosylceramide (α-GalCer). In contrast, minor adverse effects restricted to a few subjects and hepatic toxicity have been observed in clinical trials of ABC294640 and safingol, respectively. In the case of CNLs, SKI-II, fingolimod and sonepcizumab there are some limitations and absence of enough clinical studies to demonstrate a benefit. The effectiveness or lack of a major therapeutic effect of sphingolipid modulation by some drugs as a cancer therapy and other aspects related to their mechanism of action are discussed in this review
Tumor Profiling at the Service of Cancer Therapy
No full textCancer treatment; Personalized medicine; Precision oncologyTratamiento del cáncer; Medicina personalizada; Oncología de precisiónTractament del càncer; Medicina personalitzada; Oncologia de precisióCancer treatment options have evolved significantly in the past few years. From the initial surgical procedures, to the latest next-generation technologies, we are now in the position to analyze and understand tumors in a one-by-one basis and use that to our advantage to provide with individualized treatment options that may increase patient survival. In this review, we will focus on how tumor profiling has evolved over the past decades to deliver more efficient and personalized treatment options, and how novel technologies can help us envisage the future of precision oncology toward a better management and, ultimately, increased survival.This work was funded by AECC grant GC16173720CARR to ÁC, ML, and AC. Also, other sources of funding include the Fundación Ramón Areces; the Spanish Ministry of Science, Innovation and Universities (MCIU- I+D+i 2018), Spanish Research State Agency (AEI), the European Fund for Regional Development (MCIU/AEI/FEDER-UE): grants RTI2018-097455-B-I00 and RED2018-102723-T; CIBER-Onc (grant number CB16/12/00275) and the Economy, Business and Universities Council of the Junta de Andalucia (grant number P18-RT-2501)—to AC; and the Instituto de Salud Carlos III (ISCIII) co-financed by the European Regional Fund (ERDF): grant numbers PI16/01057—to AC and PI15/01262 and CP03/00101—to ML
- …
